During the past decade, Yale Nephrology Clinical Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Yale Nephrology Clinical Research" are "ADPKD" (1 trials), "Autosomal Dominant Polycystic Kidney" (1 trials) and "Polycystic Kidney Disease, Autosomal Dominant" (1 trials). Many other conditions were trialed in "Yale Nephrology Clinical Research" in a lesser frequency.

Most popular intervention types in "Yale Nephrology Clinical Research" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (1 trials), "RGLS4326" (1 trials) and "Tesevatinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Yale Nephrology Clinical Research" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Yale Nephrology Clinical Research". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Yale Nephrology Clinical Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Yale Nephrology Clinical Research, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".